Overview

Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will alleviate urinary retention secondary to BPH in who have failed a voiding trial without a catheter. Following treatment with an Alpha Blocker alone.

Phase:

N/A

Details

Lead Sponsor:

Franklin D. Gaylis, MD Inc.

Treatments:

Dutasteride